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A panel of infectious disease specialists, clinical
microbiologists and hospital epidemiologists of the
five Swiss university hospitals reviewed the current
literature on the treatment of invasive fungal infec-
tions in adults and formulated guidelines for the
management of patients in Switzerland. For empir-
ical therapy of Candida bloodstream infection, flu-
conazole is the drug of choice in non-neutropenic
patients with no severe sepsis or septic shock or 
recent exposure to azoles. Amphotericin B deoxy-
cholate or caspofungin would be the treatment 
option for patients with previous azole exposure. In
neutropenic patients, empirical therapy with am-
photericin B deoxycholate is considered first choice.
In patients with severe sepsis and septic shock,
caspofungin is the drug of first choice. For therapy
of microbiologically-documented Candida infec-
tion, fluconazole is the drug of choice for infections
due to C. albicans, C. tropicalis or C. parapsilosis. When
infections are caused by C. glabrata or by C. krusei,
caspofungin or amphotericin B deoxycholate are
first line therapies. Treatment guidelines for inva-
sive aspergillosis (IA) were stratified into primary
therapy, salvage therapy and combination therapy
in critically ill patients. Voriconazole is recom-
mended for primary (ie upfront) therapy. Caspofun-
gin, voriconazole (if not used for primary therapy)
or liposomal amphotericin B are recommended for
salvage therapy for refractory disease. Combination
therapy with caspofungin plus voriconazole or lipo-
somal amphotericin B should be considered in crit-
ically ill patients. Amphotericin B deoxycholate is
recommended as initial therapy for the empirical
therapy in patients with neutropenia and persistent
fever with close monitoring of adverse events.
Key words: guidelines; candida; invasive aspergil-
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Candida and Aspergillus are the most common
causes of invasive fungal infections, accounting for
70–90% and 10–20% of all invasive mycoses, re-
spectively [1]. In the US, the incidence of fungal
sepsis has increased three-fold between 1979 and
2000 [2]. Invasive candidiasis and aspergillosis are
associated with substantial morbidity and high
mortality (40–60% and 60–90%, respectively),
prolonged hospital stay and increased health care
costs [3–7]. Early diagnosis and prompt initiation
of antifungal therapy are thus essential to reduce
morbidity and mortality.
For decades, amphotericin B deoxycholate,
has been standard therapy for invasive fungal in-
fections. Unfortunately, amphotericin B deoxy-
cholate is often poorly tolerated and associated
with infusion-related acute reactions and nephro-
toxicity. In the late 1970s and 1980s, the emer-
gence of azoles (first miconazole and ketoconazole
and then fluconazole and itraconazole), a new class
of antifungal agents inhibiting the synthesis of 
the cell membrane, provided an alternative thera-
peutic strategy to amphotericin B deoxycholate. In 
recent years, several new antifungal agents have
become available offering additional therapeutic
options for the management of invasive fungal 
infections. These include lipid formulations (col-
loidal dispersion, lipid-complex and liposomal) of
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amphotericin B, new azoles (voriconazole, and
posaconazole) and echinocandins (caspofungin,
micafungin and anidulafungin) [8–12]. 
A recent publication has shown the utility of
using treatment guidelines to improve the out-
come of patients with invasive fungal infections
[13]. Therefore the aim of the present article is 
to review the current literature on antifungal ther-
apy and to formulate treatment recommendations
for the management of the two most frequent 
invasive fungal infections occurring in surgical,
critically ill or immunocompromised patients,
namely invasive candidiasis and invasive as pergillo-
sis and for empirical therapy of suspected fungal
infections in patients with neutropenia and persist-
ent fever. 
The article was prepared by a group of infectious dis-
eases specialists, clinical microbiologists and hospital epi-
demiologists from the five Swiss university hospitals with
expertise in the diagnosis and the management of fungal
infections. This group was founded in 2000 under the
name of the Fungal Infection Network of Switzerland
(FUNGINOS). The names of participating individuals
and institutions of FUNGINOS can be found in the Ap-
pendix of the first article published by the group on the
epidemiology of Candida infections [14]. FUNGINOS
was created with the overall objective to promote biomed-
ical research on invasive fungal infections in Switzerland.
The recommendations were presented and discussed at
meetings of the FUNGINOS group and of the Swiss 
Society of Infectious Diseases. Modifications were circu-
lated electronically and agreed upon as part of an iterative
process until consensus was reached by a majority of Steer-
ing Committee members. Treatment recommendations
were rated according to a standard scoring scheme to
illustrate the strength of the supporting evidence and the
quality of the underlying data as follows: Level of recom-
mendation: A = good evidence; B = moderate evidence; 
C = poor evidence, Quality of recommendation: I = ran-
domised, controlled, clinical study; II = non-randomised,
controlled clinical study or cohort study or case-control
study; III = case series or expert opinion [15]. 
Methods
Epidemiology 
Candida species are the most frequent cause of
fungal infections (70 to 90% of cases) and account
for 5 to 15% of health-care associated infections
[16, 17]. Risk factors for fungal sepsis include pre-
maturity, low birth weight, disruption of cutaneous
or mucosal barriers (such as surgical wounds, burns
or chemotherapy-induced mucositis), indwelling
intravascular or urinary catheters, defects of cell-
mediated immunity, broad-spectrum antibiotic
therapy, parenteral nutrition, colonisation with
Candida at multiple sites, surgery (especially gas-
trointestinal interventions) or haemodialysis
[18–21]. Critically ill and severely immunocom-
promised patients are at particularly high risk of
invasive candidiasis. Candidaemia, one of the most
frequent clinical manifestations of candidiasis, is
associated with significant morbidity, prolonged
hospital stay, high crude and attributable mortal-
ity (40% to 60% and 20 to 40%, respectively) and
increased health care costs [3, 6]. In a multivariate
analysis of mortality associated with bloodstream
infections, Candida was found to be the sole
pathogen independently associated with fatal out-
come [22]. A nationwide population surveillance
study conducted in 50 hospitals in the US between
1995 and 2002 has confirmed that Candida is the
fourth most common cause of bloodstream in-
fections, representing 9.5% of all episodes [17]. 
In contrast, recent data from Europe have shown
that Candida species were a less common cause of
bloodstream infections. Candida species ranked
number seven accounting for 3% of all blood-
stream infections in a 10-year retrospective study
carried out in Switzerland by the Fungal Infection
Network of Switzerland (FUNGINOS) [14]. In
this survey, one third of all episodes of candidaemia
occurred in ICUs (intensive care unit), one third
in medical wards, including haematology-oncol-
ogy units, and one fourth in surgical wards [14].
Microbiology 
Until recently, C. albicans was by far the pre-
dominant species causing up to two thirds of all
cases of invasive candidiasis. However, a shift to-
wards non-albicans Candida species with decreased
susceptibility or resistance to azoles, such as C.
glabrata and C. krusei, has been observed recently
in some North-American and European centres
[23–25]. The exact role of the increasing use of
azoles in this epidemiological shift remains con-
troversial [26]. In Switzerland the distribution of
Candida species has remained stable between 1991
and 2000 with C. albicans, C. glabrata and C. krusei
accounting for 66%, 14% and 2% of all cases of
candidaemia, respectively [14]. 
Identification of Candida species and antifun-
gal susceptibility testing are critical for selecting
appropriate therapy. Indeed, studies have shown
that in vitro susceptibility testing for Candida may
increase the probability of good outcome [27–36].
So far, the clinical utility of in vitro testing has been
demonstrated in experimental animal models of
candidiasis and in HIV-positive patients with
Invasive candidiasis
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oropharyngeal candidiasis [31; 37; 38]. A recent
retrospective clinical study in 32 patients with can-
didaemia reported different success rates of flu-
conazole in infections with MIC 98 mg/L (ie sus-
ceptible: success in 14/21 (67%) cases), MIC 16 to
32 mg/L (ie dose-dependent susceptible: success in
1/5 (20%) cases), and MIC >32 mg/L (ie resistant:
success in 0/6 (0%) cases) [30]. This study showed
that a fluconazole dose/MIC ratio >50 was associ-
ated with a success rate of 74% (14/21 cases) com-
pared to only 8% (1/13 cases) for a dose/MIC ratio
950. Antifungal susceptibility testing is also not
routinely available in all centres, but identification
of Candida species can be used to predict resistance
and guide therapy (table 1). Indeed, C. albicans and
other less frequent non-albicans Candida species,
such as C. tropicalis and C. parapsilosis are in general
susceptible to polyenes (amphotericin B), azoles
(fluconazole, itraconazole, voriconazole, posacona-
zole), and echinocandins (caspofungin, micafungin,
anidulafungin) [39]. In contrast, C. glabrata, the
most frequent non-albicans species, is susceptible to
amphotericin B and echinocandins, but displays re-
duced susceptibility to azoles [39]. A recent single-
centre study reported high resistance rates in 
C. glabrata: up to 60% for fluconazole, 83% for itra-
conazole, and 44% for voriconazole, respectively
[40]. C. krusei is susceptible to amphotericin B,
voriconazole, and the echinocandins, but intrinsi-
cally resistant to fluconazole and itraconazole [39]. 
Antifungal therapy
Rapid initiation of appropriate antifungal
therapy is essential for the control of systemic Can-
dida infections and has been shown to reduce mor-
tality [41–43]. Management guidelines have rec-
ommended that all patients with candidaemia,
defined as the detection of Candida in at least one
blood culture, should be treated with antifungal
agents [20, 44, 45]. 
Polyenes
Amphotericin B deoxycholate, a fungicidal agent
with broad-spectrum antifungal activity that acts
on ergosterol of the fungal cell membrane, has
been used for decades as the treatment of choice of
invasive candidiasis. It is usually used at a dose
ranging between 0.6 and 1 mg/kg/d i.v. Unfortu-
nately, amphotericin B deoxycholate is often
poorly tolerated being associated with infusion-re-
lated acute reactions (eg chills, fever, hypoxaemia,
and hypotension), especially when administered
over a short period of time (ie 4 to 6 hours), and
with nephrotoxicity (decreased glomerular filtra-
tion and tubular wasting of potassium, magnesium,
and bicarbonate). However, four recent studies
have shown that administration of amphotericin B
deoxycholate as a continuous infusion over 
24 hours with saline loading reduced infusion-
related reactions and renal impairment, including
in allogenic stem cell transplant patients receiving
cyclosporin A [46–49]. Also, a multivariate analy-
sis on the epidemiology of renal toxicity in 494 pa-
tients receiving amphotericin B deoxycholate
showed that male gender, body weight 090 kg,
chronic renal disease, treatment with an aminogly-
cosides or cyclosporin and doses of amphotericin
B 035 mg/day were independent risk factors for
nephrotoxiciy. Of note, the incidence of nephro-
toxicity rose with the increasing number of risk
factors suggesting that alternative therapy might
be appropriate in patients with 2 or more risk fac-
tors [50, 51].
Lipid formulations of amphotericin B (col-
loidal dispersion, lipid-complex and liposomal) are
better tolerated than amphotericin B deoxycholate
and have been used mainly in patients intolerant to
conventional amphotericin B or unlikely to tolerate
it because of already altered renal function [9,
52–55]. Only liposomal amphotericin B (Am-
Bisome®) is available in Switzerland. Few studies
have compared the efficacy of amphotericin B de-
oxycholate with that of lipid formulations for the
treatment of patients with invasive candidiasis.
Small non-comparative studies suggest that lipid
formulations of amphotericin B are as efficacious 
as conventional amphotericin B [56–59]. High
costs, a relative paucity of clinical data and the exis-
tence of alternative antifungal therapies (azoles and
echinocandins) explain why lipid formulations have
been generally used as second-line therapy in pa-
tients with refractory invasive candidiasis [20, 45].
Azoles 
In the late 1980s triazoles rapidly became stan-
dard therapy for invasive candidiasis. Azoles in-
hibit the synthesis of ergosterol of the fungal cell
membrane. In vitro, these compounds are fungista-
tic against Candida species. Several clinical studies
have compared the efficacy and safety of azoles
Candida spp. Fluconazole Itraconazole Voriconazole Amphotericin B Caspofungin
C. albicans S S S S S
C. tropicalis S S S S S
C. parapsilosis S S S S S *
C. glabrata S-DD to R S-DD to R S to I S to I S
C. krusei R S-DD to R S S to I S
C. lusitaniae S S S S to R S
Note: Interpretation based on the use of the NCCLS (CLSI) M27-A methodology 
S: susceptible; S-DD: susceptible-dose dependent; I: intermediate; R: resistant
* MIC90 higher than in other Candida species, but clinical significance unknown (breakpoints not yet defined)
Table 1
General pattern 
of susceptibility of
Candida species
(adapted from [20]).
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with that of amphotericin B deoxycholate for the
treatment of candidaemia in non-neutropenic pa-
tients, but few data are available on the treatment
of neutropenic patients.
Fluconazole (Diflucan®) is available as intra-
venous and oral formulations. Oral fluconazole is
very well absorbed and the bioavailability is not in-
fluenced by H2 blocking agents. The daily dose
should be reduced by half in patients with creati-
nine clearance of less than 50 ml/min and by 75%
if less than 20 ml/min. A loading dose of twice the
daily dose is recommended. In a multicentre study
of 206 non-neutropenic patients with candi-
daemia, fluconazole was found to be as efficacious
as (success rates: 72% vs 79%, respectively) and
better tolerated than amphotericin B deoxycholate
[60]. Given the broad use of fluconazole, an in-
creasing incidence of infections due to non-albicans
Candida species with reduced, dose-dependent,
susceptibility (C. glabrata) or intrinsic resistance
(C. krusei) to azoles has been reported in the late
1990s [17, 25, 61]. Data on the efficacy of high
doses (800 to 1200 mg) of fluconazole for the treat-
ment of suspected azole-resistant Candida blood-
stream infections are lacking.
Itraconazole is available as oral and intra-
venous formulations. However, the poor bioavail-
ability (enhanced by food) of its original oral for-
mulation has limited its use and no comparative
clinical studies have been performed in patients
with candidaemia. An intravenous formulation of
itraconazole has recently become available, but few
clinical data have assessed its efficacy and safety.
Given the variation in its bioavailability and poten-
tial for drug-drug interactions (eg with rifampicin,
anticonvulsants, protease-inhibitors, macrolides)
it is recommended to monitor itraconazole blood
levels during therapy.
Voriconazole is available as oral (bioavailabil-
ity 60 to 100%) and intravenous formulations [10].
It is metabolised in the liver via the P-450 system
(CYP2C9, CYP3A4 and CYP2C19), hence the
potential for multiple drug interactions (eg with
rifampicin, anticonvulsants, sirolimus, tacrolimus,
cyclosporin, oral anticoagulants, statins, omepra-
zole, protease-inhibitors, NNRTI). There is no
need to alter voriconazole doses in patients with
renal impairment receiving the oral formulation.
However, administration of intravenous voricona-
zole in patients with moderate renal insufficiency
(creatinine clearance of less than 50 ml/min) 
may result in accumulation of the b-cyclodextrin 
used to solubilise voriconazole. Adverse events
include transient and fully reversible, non-sight-
threatening visual disturbances (in about 30 to
40% of patients), rash, hepatitis, and hallucina-
tions. Voriconazole exhibits excellent in vitro
and in vivo activities against Candida species [39].
Clinical data from immunocompromised (mainly 
HIV-positive) patients with oropharyngeal and/or 
oesophageal candidiasis suggest that voriconazole
has excellent activity against fluconazole-suscepti-
ble and fluconazole-resistant Candida infections:
98% success of voriconazole versus 95% success of
fluconazole [62]. Voriconazole salvage therapy
showed an overall success rate of 55% in patients
with refractory systemic candidiasis [63]. In a ran-
domised, open-label, comparative multicentre
non-inferiority trial in 422 patients with invasive
Candida infections (of whom >95% had candi-
daemia), voriconazole was shown to be at least as
effective as a regimen of amphotericin B deoxy-
cholate followed by intravenous or oral flucona-
zole [64]. Of note, for C. tropicalis infections, 
success rates were higher with voriconazole than
with amphotericin B/fluconazole (P = 0.03). 
Posaconazole is a new azole with broad-spec-
trum antifungal activity against Candida, Asper-
gillus, and other emerging molds including Fusa-
rium and the zygomycetes. The hepatic metabolic
pathways of posaconazole differ from those of
other azoles: glucuronation plays a major role,
while enzymes of the CYP450 system are of 
secondary importance, which may decrease the
risk of clinically significant drug-drug interactions
[65]. The drug is available in oral form with 
variable bioavailability, which can be significantly
improved (ie up to 90%) by food intake [66]. 
In 199 HIV-positive patients with azole-refrac-
tory oropharyngeal or oesophageal candidiasis,
posaconazole 400 mg twice daily was clinically 
successful in 75% of cases (modified ITT analysis)
and 81.6% of cases (evaluable population) [67]. 
In another clinical study, the success rate of
posaconazole as salvage therapy in patients with
invasive candidiasis was 47.8% [68]. In a long-term
safety study in 102 patients treated with posacona-
zole for salvage therapy of invasive mycoses seri-
ous adverse events occurred in 12/102 (12%) pa-
tients, but only in one case posaconazole therapy
was discontinued [69]. Although posaconazole will
be soon approved for salvage therapy of refractory
mycoses, clinical data from comparative studies on
first-line therapy of candidiasis are needed.
Echinocandins
Echinocandins are a new class of parenteral
antifungal agents that act by inhibiting the glucane
synthase, the enzyme responsible for the synthesis
of b-(1,3)-D-glucan in the fungal cell wall [12].
These compounds are fungicidal in vitro against 
C. albicans and non-albicans Candida species. No
cross-resistance with azoles has been reported.
Caspofungin is the first echinocandin licensed
for the treatment of invasive mycoses, including
candidiasis [12]. It is only available as an intra-
venous formulation. Caspofungin is taken up by
the liver and is slowly degraded by hydrolysis and
N-acetylation. Therefore, there is no need for
dose adjustments in patients with renal insuffi-
ciency, but dose reduction to 35 mg is recom-
mended in patients with moderate hepatic dys-
function. No data are available in patients with 
severe impairment of liver function or in children.
Safety profile of caspofungin is excellent with few
reported adverse events (mostly abnormal liver
S W I S S  M E D  W K LY 2 0 0 6 ; 1 3 6 : 4 4 7 – 4 6 3  ·  w w w. s m w. c h 451
function tests, phlebitis or histamine-like reac-
tions). Drug-drug interactions with some medica-
tions have been observed (eg with rifampicin, an-
ticonvulsants, tacrolimus, cyclosporin, protease-
inhibitors, NNRTI). In immunocompromised
(mainly HIV-positive) patients with oropharyn-
geal and/or oesophageal candidiasis caspofungin
was found to be as effective (success rates: 70 to
90%) as amphotericin B deoxycholate (success
rate: 65%) or fluconazole (success rate: 80%)
[70–72]. In a large multicentre trial that included
239 patients (of whom 24 were neutropenic) with
invasive candidiasis, caspofungin was at least as 
efficacious as and less toxic than amphotericin B
deoxycholate (success rates: 73% vs 62%; discon-
tinuation for adverse events: 3% vs 23%) [73]. 
Of note, the success rates of caspofungin against 
C. glabrata and C. krusei were comparable to those
obtained in azole-susceptible Candida species. 
Micafungin and anidulafungin. Micafungin
has been approved in Japan and recently by the
FDA for prophylaxis of Candida infections in pa-
tients undergoing haematopoietic stem cell trans-
plantation and for the treatment of oesophageal
candidiasis. Approval in Europe is pending. Anidu-
lafungin is in clinical development. In randomised,
double-blind studies, the efficacy of micafungin
(50, 100 or 150 mg/d; success rates: 70–90%, or
anidulafungin (100 mg, followed by 50 mg/d; 
success rate: 97%) was found to be comparable to
that of fluconazole (200 mg, followed by 100 mg/d;
success 85–95%) for the treatment of oesopha-
geal candidiasis in immunocompromised (mainly
HIV-positive) patients [74, 75]. Micafungin was
reported to yield 100% response rates in a small 
non-comparative series of six cases of candidaemia
[76]. In an open-label, non-comparative, interna-
tional study of patients with newly diagnosed or re-
fractory candidiasis, micafugin was associated with
an overall success rate of 83.3% [77]. Success rates
of 84 to 90% have been observed in a phase II,
dose-finding, study of anidulafungin for the treat-
ment of 68 patients with invasive candidiasis [78].
In a randomised, double-blind phase III study of 
245 adult patients with invasive candidiasis anidu-
lafungin treatment was statistically superior to flu-
conazole (success rates at end of i.v. therapy 75.6%
vs 60.2%, difference 15.4%, 95% Cl 3.8 to 27).
Persistence of candidaemia at the end of i.v. ther-
apy was reported in 6.3% and 14.4% of patients
receiving anidulafungin and fluconazole, respec-
tively. Survival at 6 weeks was higher in the anidu-
lafungin than in the fluconazole treatment group
(75% vs 69%) [79].
Combinations of antifungal agents
Given the poor prognosis of Candida sepsis,
clinicians have shown great interest for using com-
binations of antifungal agents of different classes
for the treatment of critically ill patients. However,
until now there have been relatively few studies 
on combinations of antifungal agents in invasive
candidiasis. Some experts recommend the com-
bination of amphotericin B deoxycholate and 
5-flucytosine for the treatment of life-threatening
Candida infections [20, 44, 45]. This recommenda-
tion is based on the demonstration of synergistic
effects in in vitro studies and in experimental ani-
mal models of systemic candidiasis and Candida en-
docarditis [80–82]. Combinations of amphotericin
B and 5-flucytosine have been shown to be supe-
rior to monotherapy for therapy with cryptococ-
cal infections in immunocompromised patients,
but there are few data in patients with invasive
Candida infections [83–90]. Given the lack of evi-
dence on clinical efficacy, concerns about toxicity
(impairment of renal function by amphotericin B
may lead to accumulation of flucytosine and in-
creased toxicity) and the recent development of
new therapeutic options in critically patients, com-
bined amphotericin B deoxycholate and 5-flucyto-
sine therapy is not recommended. Despite in vivo
antagonism between amphotericin B and azoles in
experimental models of aspergillosis [91–93], data
obtained in animal models of invasive candidiasis
and Candida endocarditis did not show antago-
nism, but also no synergism [91–93]. In a ran-
domised, double-blind study in 219 non-neu-
tropenic patients with candidaemia, fluconazole
(800 mg/d i.v.) was compared to a combination 
of fluconazole (800 mg/d i.v.) and amphotericin B
deoxycholate (0.7 mg/kg/d i.v.) [94]. At first glance,
the efficacy of combination therapy was slightly
superior to that of monotherapy (success 69% vs
56%). However, there were statistically significant
differences in baseline covariates between the two
treatment groups, such as diseases severity as
measured by the APACHE II score, which was
lower in the combination group. While awaiting
the results of prospective, randomised clinical tri-
als demonstrating that combinations of antifungals
are superior to and no more toxic than treatment
with single agents, the indiscriminate use of com-
bined regimens should be discouraged.
1. Empirical therapy for Candida blood-
stream infections (table 2A and figure 1A)
An algorithm for choosing an empirical anti-
fungal treatment for patients with Candida blood-
stream infection (before information about species
identification and susceptibility becomes available)
is shown in figure 1A. Several factors should 
be taken into account that may help physicians
when choosing an antifungal agent for empirical
therapy. These includes local epidemiological
data, prior exposure to antifungal therapy, pres-
ence of neutropenia, severity of the clinical pres-
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entation (presence of sepsis, severe sepsis or septic
shock) and presence of underlying diseases or
organ dysfunctions that may affect drug metabo-
lism or increase the risk of drug-related toxicities.
Treatment recommendations have been developed
for four clinical conditions covering most of the
circumstances encountered by practicing physi-
cians: 1) absence of neutropenia, of severe sepsis or
septic shock, or of recent exposure to azoles, 2)
previous exposure to azoles, 3) presence of neu-
tropenia, and 4) presence of severe sepsis or septic
shock.
1.1. Absence of neutropenia, severe sepsis or
septic shock or recent exposure to azoles. Flucona-
zole is the drug of choice in haemodynamically-
stable, non-neutropenic patients at low risk for
azole-resistant Candida species. Alternative thera-
pies are amphotericin B deoxycholate, caspofun-
gin and voriconazole.
1.2 Recent exposure to azoles. A recent expo-
sure to azoles increases the risk of an infection 
due to non-albicans Candida, such as C. glabrata
or C. krusei, that exhibit reduced susceptibility 
(C. glabrata) or are resistant (C. krusei) to azoles. 
In patients in whom infections may be caused by
azole-resistant non-albicans Candida species fol-
lowing previous therapy with azoles, amphotericin
B deoxycholate or caspofungin are therefore rec-
Setting First choice Alternatives Switch to oral therapy
Non-neutropenic patient
No previous exposure Fluconazole (Diflucan®) 800 mg i.v. Amphotericin B deoxycholate (Fungizone®)* According to species identification
to azoles (1st dose),  then 400 mg/d i.v., 1 mg/kg/d i.v., Grade: AI, and susceptibility testing
Grade: AI or Caspofungin (Cancidas®) 70 mg i.v. (1st dose), Grade: CIII
then 50 mg/d i.v., Grade: AI, 
or Voriconazole (Vfend®) 6 mg/kg q12h i.v. on day 1, 
then 4 mg/kg 2x/d i.v., Grade: AI
Previous exposure Amphotericin B deoxycholate (Fungizone®)* Liposomal Amphotericin B (AmBisome®) According to species identification
to azoles 1 mg/kg/d i.v., Grade: BI 3 mg/kg/d i.v., Grade: BII and susceptibility testing
or Caspofungin (Cancidas®) 70 mg i.v. Grade: CIII
(1st dose), then 50 mg/d i.v., Grade: BI
Neutropenic patient Amphotericin B deoxycholate (Fungizone®)* Caspofungin (Cancidas®)1 (see Table 2B) 70 mg i.v. According to species identification, 
1 mg/kg/d i.v., Grade: CIII (1st dose, then 50 mg/d i.v., Grade: CIII susceptibility testing and bone
or Liposomal Amphotericin B (AmBisome®) marrow recovery (see footnote 1,
3 mg/kg/d i.v., Grade: CIII Table 2B), Grade: CIII
Severe sepsis or Caspofungin (Cancidas®)1,2 (see Table 2B) Liposomal Amphotericin B (AmBisome®) 3 mg/kg/d i.v. Continue i.v. therapy until patient
septic shock 70 mg i.v. (1st dose), then 50 mg/d i.v. Grade: CIII is in stable condition, then adjust
Grade: CIII or IF NO PREVIOUS AZOLE EXPOSURE1,3 (see Table 2B): therapy according to species
Voriconazole (Vfend®) 6 mg/kg q12h i.v. on day 1, identification and susceptibility 
then 4 mg/kg 2x/d i.v., Grade: CIII and susceptibility testing
testing (see footnote 1, Table 2B)
* See general comments in the footnote of table 4.
Table 2A
Empirical therapy for Candida bloodstream infections.
Species Susceptibility testing First choice Alternatives Switch to oral medication
C. albicans Fluconazole S Fluconazole (Diflucan®)1 Amphotericin B deoxycholate (Fungizone®)*,2 Fluconazole (Diflucan®) 
C. tropicalis Fluconazole S 800 mg i.v. (1st dose) then 400 mg/d i.v. 1 mg/kg/d i.v., Grade: AI (BI for C. tropicalis 400 mg/d1 or generic formu-
C. parapsilosis Fluconazole S Grade: AI (BI for C. tropicalis and and C. parapsilosis) lations, Grade: A
C. parapsilosis) or Caspofungin (Cancidas®)1,2, 70 mg i.v. (BI for C. tropicalis and
(1st dose), then 50 mg/d i.v., Grade: A C. parapsilosis)
(BI for C. tropicalis and C. parapsilosis)
or Voriconazole (Vfend®)1, 6 mg/kg q12h i.v. 
on day 1, then 4 mg/kg 2x/d i.v., Grade: AI
(BI for C. tropicalis and C. parapsilosis)
C. glabrata Fluconazole S/S-DD/R Amphotericin B deoxycholate Liposomal Amphotericin B (AmBisome®) Itraconazole (Sporanox®)1,3,4
C. krusei Fluconazole R (Fungizone®)*,2, >1 mg/kg/d i.v. 3 mg/kg/d i.v., Grade: BI 400 mg/d, Grade: CIII
Grade: BI or Voriconazole (Vfend®)1,3 (only for C. krusei) or Voriconazole (Vfend®)1,3,4
or Caspofungin (Cancidas®)1, 2 6 mg/kg q12h i.v. on day 1, then 4 mg/kg 400 mg/d, Grade: CIII
70 mg i.v. (1st dose), then 50 mg/d i.v. 2x/d i.v., Grade: BI
S: susceptible; S-DD: susceptible-dose dependent; R: resistant. The evidence that in vitro susceptibility of C. glabrata to fluconazole predicts clinical response 
is lacking.
* See general comments in the footnote of table 4.
1 Few clinical data are available on the use of azoles and echinocandins in neutropenic patients with documented invasive candidiasis. In vitro, azoles are fungistatic,
echinocandis are fungicidal. In some experimental models (eg Candida endocarditis, disseminated candidiasis in neutropenic animals), azoles are less efficacious 
than amphotericin B or echinocandins.
2 Amphotericin B deoxycholate (Fungizone®) not recommended in critically ill patients with severe sepsis/septic shock: risk of acute nephrotoxicity or 
of underdosing due to infusion-related toxicity. Caspofungin (Cancidas®) = first choice or alternative, respectively, in this setting.
3 According to susceptibility testing. Some experts would add voriconazole to the list of first choice agents for the treatment of C. glabrata infections.
4 For C. glabrata switch to oral itraconazole or voriconazole only after resolution of clinical symptoms/signs of infection and only if susceptibility test shows 
MIC ≤0.5 mg/L for itraconazole) or ≤1.0 mg/L for voriconazole, respectively.
Table 2B
Therapy for microbiologically-documented Candida infections.
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ommended as first choice agents for empirical
therapy. Contraindications for using amphotericin
B deoxycholate are listed in the footnote of table
4. Alternative therapies are caspofungin or liposo-
mal amphotericin B. 
1.3. Neutropenia. Few data are available on
the clinical efficacy of antifungal agents in neu-
tropenic patients with candidaemia. Data from 
experimental models in animals with Candida
endocarditis or invasive candidiasis in the context 
of neutropenia suggest that fungicidal agents, such
as amphotericin B or caspofungin, might be more
efficacious than fungistatic drugs like azoles 
[93, 95]. Moreover, lower reponse rates have been
reported in neutropenic compared with non-neu-
tropenic patients with candidaemia [25, 96, 97].
Given that it might be preferable to use fungicidal
agents in neutropenic patients, amphotericin B 
deoxycholate is proposed as first choice in patients
without contraindications (see footnote table 4).
Lipid formulations of amphotericin B and caspo-
fungin are alternative therapies. 
1.4. Severe sepsis and septic shock. Empirical
antifungal therapy active against albicans and non-
albicans Candida species (including species with de-
creased susceptibility to azoles accounting for 15%
to 20% of all episodes in Switzerland) is required
in patients with yeast bloodstream infections 
complicated by severe sepsis or septic shock [14].
Nephrotoxic agents should be avoided given 
the risk of development of renal failure in the
haemodynamically unstable, septic patient. De-
spite limited clinical experience in this setting,
caspofungin is the drug of first choice due to its
excellent efficacy and safety profiles. Alternative
therapies comprise lipid formulations of ampho-
tericin B or voriconazole in patients not recently
exposed to azoles. 
2. Therapy for microbiologically-documented
Candida infections (table 2B and figure 1B)
Although antifungal susceptibility tests are not
performed routinely in all medical centres, suscep-
tibility can usually be estimated upon identifica-
tion of the Candida species. 
For infections caused by C. albicans, C. tropi-
calis or C. parapsilosis, fluconazole is the drug of
choice. Switch to oral therapy is recommended
CaspofunginFluconazole
Yeasts in blood cultures
Severe sepsis/
septic shock
Non-neutropenic
No azole
prophylaxis
Azole
prophylaxis
Amphotericin B
deoxycholate*
Neutropenic
Amphotericin B
deoxycholate*
or Caspofungin
Figure 1A
Detection of Candida
in blood cultures:
empirical antifungal
therapy before 
identification of 
Candida species.
For dosages and 
alternative drugs 
see table 2A.
* Amphotericin B 
deoxycholate should
not be used if contra-
indications are
present (see general
comments in the
footnote of table 4).
Identification of Candida species and
susceptibility testing
C. albicans
C. tropicalis
C. parapsilosis
C. krusei
C. glabrata
Fluconazole* Amphotericin B
deoxycholate**
or Caspofungin
Figure 1B
Invasive candidiasis:
treatment options
once species identity
and susceptibility are
known.
For dosages and 
alternative drugs 
see table 2B.
* Fluconazole is fungistatic in vitro and is less 
efficacious than amphotericin B and echino-
candins in some experimental models of infec-
tion (eg Candida endocarditis, disseminated
candidiasis in neutropenic animals). As clinical
data on its efficacy in neutropenic patients with
systemic candidiasis are lacking, some experts
recommend the use of fungicidal drugs 
(ie amphotericin B, caspofungin) in this setting.
** If contraindications present / in critically ill 
patients (risk of acute nephrotoxicity / 
of underdosing due to infusion-related toxicity)
amphotericin B deoxycholate  should not 
be used (see general comments in the footer 
of table 4).
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once the patient has improved and is able to take
an oral medication. Amphotericin B deoxycholate,
caspofungin or voriconazole are alternative treat-
ment options. Although there are no clinical data
to support this recommendation, some experts
would prefer using fungicidal agents (caspofungin
or amphotericin B) for treating neutropenic 
patients with Candida bloodstream infections or
with invasive candidiasis. However, amphotericin
B deoxycholate should be avoided in critically ill
patients at high risk of developing renal failure or
in whom infusion-related toxicity might delay 
administration of efficacious doses. 
For infections caused by C. glabrata (inde-
pendently of the results of in vitro susceptibility
testing for fluconazole) or by C. krusei, caspofun-
gin or amphotericin B deoxycholate are first choice
therapies. Alternative therapies are lipid formula-
tions of amphotericin B or voriconazole. However,
fluconazole-resistant C. glabrata may be or may
rapidly become cross-resistant to voriconazole
[98] (J. Bille, unpublished observation). Suscepti-
bility should therefore be checked before using
voriconazole for the treatment of C. glabrata in-
fections. As soon as the patient is clinically stable
and is able to take an oral medication, a switch to 
either itraconazole or voriconazole should be con-
sidered, provided that the isolate is susceptible. 
Duration of therapy. For primary blood-
stream Candida infections, it is recommended to
treat patients for two weeks after the last positive
blood culture. In case of invasive candidiasis with
involvement of one or more organs (eg liver,
spleen, lung, skin, eye, or bone), therapy should be
continued until complete resolution of clinical
symptoms and signs at all sites of infection.
Epidemiology
Invasive aspergillosis (IA) is the second most
common invasive mycosis accounting for 10 to 20%
of all cases. This potentially life-threatening infec-
tion occurs mainly in immmunocompromised hosts,
including neutropenic cancer patients, haemato-
poetic stem cell (HSCT) or solid organ transplant 
recipients, especially those with severe graft-versus-
host disease (GVHD), patients treated with im-
munosuppressive therapies (corticosteroids, cyto-
toxic agents or monoclonal antibodies acting as 
anti-immune mediators) [7]. The highest incidence 
(10 to 20%) and mortality (60 to 90%) rates of 
IA have been reported in allogeneic HSCT and in
heart, lung or heart/lung transplant recipients [7, 99,
100]. Apart from the classical immunocompromised
host, IA has been recently recognised to occur in a
growing number of critically ill patients receiving
corticosteroids for treatment of chronic lung dis-
eases, including mechanically-ventilated intensive
care unit patients [101]. In a recent report, 3.6% of
1850 medical ICU patients developed invasive as-
pergillosis, which was associated with a mortality 
of 80% [102]. Of note, several of these patients did
not have classical risk factors, but various underly-
ing conditions including liver cirrhosis. The most
frequent site of IA is the lower respiratory tract 
accounting for about 80 to 90% of all cases. Other
classical clinical manifestations include sinusitis,
central nervous system (CNS) infections and dis-
seminated infection involving multiple sites [7, 99]. 
Standardised definitions of IA were recently
established by an expert panel of the EORTC and
the MSG [103]. Based on clinical, radiological and
microbiological criteria, cases of IA are classified
into one of three categories: possible, probable or
proven IA. However, these definitions have been
primarily developed for clinical research, and their
usefulness for management strategies remains to
be determined.
Microbiology
A. fumigatus is the predominant Aspergillus
species isolated in patients with IA (accounting for
more than 90% of cases in many series), followed
by A. flavus, A. terreus and A. niger [104]. However,
a shift in the epidemiology of Aspergillus infections
has been recently observed with an increasing 
frequency of infections caused by non-fumigatus
Aspergillus species, such as A. terreus which is re-
sistant to amphotericin B [105]. A. terreus is more
often a health-care-associated than a community-
acquired infection and has been associated with
lower response rates to antifungal therapy when
compared to A. fumigatus (28% versus 39%). Sig-
nificant progress has been made in in vitro suscep-
tibility testing for molds, including Aspergillus
[106–109]. Yet, it is still a research tool performed
in a few laboratories with special expertise in 
the field and clinical studies on in vitro and in vivo
correlations remain to be conducted.
Antifungal therapy 
Antifungal agents licensed for the treatment 
of invasive aspergillosis (IA) are amphotericin B
deoxycholate, the lipid formulations of amphoter-
icin B, voriconazole, itraconazole and caspofungin.
Clinical data on their efficacy and safety profiles
are mainly derived from patients with pulmonary
aspergillosis, the most frequent form of IA. Since
the mortality of IA ranges between 60 and 90%, an
aggressive diagnostic approach (radiological imag-
ing, cultures, determination of galactomannan and
histopathological examinations of biological fluids
or tissue biopsies), followed by prompt institution
of an appropriate first-line antifungal therapy is
critical [7, 104, 110, 111].
Invasive aspergillosis
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Amphotericin B
For decades, amphotericin B deoxycholate has
been standard therapy of IA [112], but response
rates have been disappointing, especially in pa-
tients with profound and persistent neutropenia or
with graft-versus-host disease. In a review of 1941
cases, crude mortality rates of 60%, 26%, and 88%
were reported in immunocompromised patients
with pulmonary, sinus, and cerebral aspergillosis,
respectively. In patients with invasive pulmonary
aspergillosis, who had been treated for more than
14 days, response rates were 83% in heart or renal
transplant recipients, 54% in leukaemic patients,
33% in HSCT, and 20% in liver transplant recip-
ients [7]. Underdosing and treatment interrup-
tions due to infusion-related and renal toxicity may
affect the efficacy of amphotericin B deoxycholate
therapy. In particular, nephrotoxicity requiring
haemodialysis has been independently associated
with death [113]. 
Lipid-based formulations of amphotericin B
are better tolerated than amphotericin B deoxy-
cholate. Outside clinical trials, lipid formulations
of amphotericin B have been used primarily as sal-
vage therapy in patients intolerant of or failing
therapy with amphotericin B deoxycholate [52,
114, 115]. Although lipid formulations of ampho-
tericin B have recently become the new standard
comparator in clinical trials of empirical therapy in
persistently febrile neutropenia, there are very few
randomised studies comparing lipid forms to am-
photericin B deoxycholate as first-line therapy of
IA. In a randomised double-blind study in 174
immunocompromised patients with invasive as-
pergillosis similar success rates were obtained with
amphotericin B colloidal dispersion (35%) and
amphotericin B deoxycholate (35%) [116]. A study
comparing a 1 to a 4 mg/kg/d i.v. dose of lipo-
somal amphotericin B (AmBisome®) as first-line
therapy of IA in 87 patients yielded similar survival
rates (43 and 37%) [117]. Lastly, a recent prospec-
tive, randomised study comparing a high dose 
(10 mg/kg/d) to a standard dose (3 mg/kg/d) of li-
posomal amphotericin B for the treatment of in-
vasive filamentous fungal infections yielded simi-
lar success and survival rates [118]. Overall, all the
available data suggest that lipid formulations are at
least as efficacious as and better tolerated than 
amphotericin B deoxycholate for the treatment of
IA [53, 112]. 
Azoles
Itraconazole has been used as first-line treat-
ment of invasive aspergillosis in few small non-
comparative studies. In 76 patients with IA, oral
itraconazole therapy resulted in a response rate of
39% [119]. A response rate of 48% was reported
in a study of 31 patients with IA who were treated
with itraconazole [120]. The highly variable
bioavailability of oral itraconazole and risk of
drug-drug interactions (eg with immunosuppres-
sive drugs) also are serious drawbacks for the treat-
ment of patients with life-threatening infections.
Monitoring of blood levels is therefore mandatory.
Itraconazole has thus been mainly used as step-
down oral therapy in patients with IA who had 
responded to initial i.v. antifungal therapy [121]. 
Voriconazole is the present treatment of first
choice for IA, and is available as intravenous and
oral formulations. In a non-comparative study of
first- or second-line treatment of IA in 116 pa-
tients, treatment with voriconazole was found to
be associated with response rates of 48% [122].
The efficacy and safety of upfront therapy with
voriconazole was compared to that of ampho-
tericin B deoxycholate in the largest (277 patients),
prospective, multicentre, randomised, compara-
tive study of IA ever performed. After 12 weeks 
of protocol therapy with or without switch to 
other licensed antifungal agents due to failure or
toxicity, success and survival rates were signifi-
cantly better in the voriconazole group than in 
the amphotericin B group (53% versus 32% and
71% versus 58%, respectively) [123]. Moreover,
fewer severe adverse events occurred in patients
treated with voriconazole than in those treated
with amphotericin B. There is substantial intra-
and inter-individual variability in voriconazole
blood levels: low levels have been observed, in par-
ticular in children, whereas elevated levels have
been measured in patients with adverse events
[122, 124–129]. Interactions with co-medications
with hepatic metabolism (listed in the section 
on invasive candidiasis) may necessitate close clin-
ical monitoring.
Posaconazole, a new azole antifungal agent
was studied as salvage therapy of invasive as-
pergillosis in 107 patients refractory to or intoler-
ant of first-line antifungal therapy [68]. Posacona-
zole was successful in 42% of patients. Response
rates in high-risk subgroups were 24% in neu-
tropenic patients and 31% in allogeneic HSCT 
recipients. Overall the 12-month survival was
45%. A salvage, open-label, compassionate study
in 23 solid-organ transplant recipients with inva-
sive mycoses refractory to or intolerant of standard
therapy reported a complete or partial response in
57% of cases [130]. Drug-drug interactions in-
creasing blood levels of cyclosporine or tacrolimus
were observed in 3 cases and lead to discontinua-
tion of posaconazole in one patient. A recent dou-
ble-blind multicentre study in 600 allogeneic
HSCT recipients compared posaconazole and flu-
conazole for prophylaxis of invasive mycoses [131].
The incidence of invasive aspergillosis during the
16-week study period was significantly lower in the
posaconazole group (2% vs 7%). The mortality
due to invasive mycoses was 1% vs 4%, respec-
tively. Adverse events occurred in 33% of cases in
both groups, and resulted in therapy discontinua-
Polyenes
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tion in 3% of patients receiving posaconazole vs
8% in those receiving fluconazole. Awaiting results
from comparative studies of first-line therapy of
invasive aspergillosis, posaconazole will be soon
available as salvage therapy of refractory invasive
mycosis.
Echinocandins
Caspofungin has been licensed for salvage ther-
apy of IA after it was shown to be efficacious and
safe in 83 patients with haematological malignan-
cies, allogeneic blood and marrow transplantation
or solid organ transplantation, who were refractory
(86%) to, or intolerant (14%) of conventional anti-
fungal therapy [132]. Complete and partial re-
sponses to caspofungin were observed in 4 (5%) and
33 (40%) of these 83 patients. Treatment was well
tolerated with minimal drug-related toxicity (clini-
cal: 12%, laboratory: 14%). A non-comparative
study on caspofungin for first-line therapy of inva-
sive aspergillosis in 32 immunocompromised pa-
tients with haematological malignancies reported a
complete or partial response in 56% of cases [133].
IA-related mortality was 22%. Comparative clini-
cal studies of first-line caspofungin therapy for pa-
tients with IA are needed. The Infectious Diseases
Group of the European Organization for Research
and Treatment of Cancer (EORTC-IDG) is cur-
rently conducting such a study.
Other echinocandins. In a non-comparative
trial conducted in Japan in 19 patients with vari-
ous forms of IA, success rates of micafungin were
60% to 67% [76]. 
Combination therapy
Given the poor prognosis of IA in immuno-
compromised patients, using combinations of an-
tifungal drugs would seem a logical approach to
improve patient’s outcome. However, there are few
clinical data supporting this approach. A few re-
ports (consisting mainly of case reports and sub-
groups of patients in case series) of combination
therapy in patients with IA suggest that liposomal
amphotericin B plus caspofungin or voriconazole
plus caspofungin may improve the outcome of 
patients with refractory IA [82, 134–136]. A recent
case-control study reported improved survival 
of patients with refractory, probable or proven 
IA treated with a combination of voriconazole 
and caspofungin compared with voriconazole
monotherapy [137]. In a multicentre, noncompar-
ative salvage study in 53 adult patients with proven
or probable invasive aspergillosis refractory or in-
tolerant to first-line antifungal therapy the combi-
nation of caspofungin with amphotericin B, itra-
conazole, or voriconazole was successful in 50%,
43%, and 60% of cases, respectively [138]. Success
rates in patients with neutropenia or allogeneic
haematopoietic stem cells transplant were 57%
and 54%, respectively. The combinations were
well tolerated, serious drug-related adverse events
occurred in only 3% of cases. A case-control study
compared the combination of voriconazole and
caspofungin (n = 34) with a monotherapy with a
lipid form of amphotericin B (n = 38) in solid organ
transplant recipients with invasive aspergillosis
[139]. A significant reduction of 90-day mortality
in the combination group was reported (26% vs
50%). In high-risk patients (ie dialysis, retrans-
plantation, or disseminated aspergillosis) mortal-
ity was 23% in the combination group and 79% 
in the control group. However, large, prospective,
randomised, comparative studies are needed to 
determine whether combination therapy is indeed
superior to monotherapy. 
1.1. Primary (ie upfront) therapy for invasive
aspergillosis. An intensive diagnostic work-up of
the patient is recommended to determine the 
aetiology of infection in patients suspected of in-
vasive aspergillosis. A recent report showing the
limited efficacy of salvage antifungal therapy in pa-
tients suffering of IA has highlighted the impor-
tance of an appropriate upfront therapy [111].
Voriconazole is first choice for upfront therapy of
IA. Keeping in mind the interindividual variations
of voriconazole pharmacokinetics, monitoring
blood levels may be considered in patients who do
not respond to therapy or in those suspected of de-
veloping drug-related adverse events. Alternative
therapies are liposomal amphotericin B and am-
photericin B deoxycholate. It is recommended to
continue therapy until complete clinical and radi-
ological resolution of infection.
Switch to oral itraconazole or voriconazole
should be considered as soon as the patient shows
signs of improvement and is able to take oral drugs
as it will significantly reduce treatment costs.
Monitoring of itraconazole blood levels is rou-
tinely recommended. 
1.2. Refractory invasive aspergillosis (ie sal-
vage therapy). Caspofungin, voriconazole (if not
used as primary therapy) and liposomal ampho-
tericin B are treatment options for salvage therapy
of IA in patients with refractory disease.
1.3. Combination therapy in critically ill 
patients. Combination therapy of caspofungin
with either voriconazole or liposomal ampho-
tericin B is recommended in critically ill patients
presenting with severe (ie life-threatening) IA. 
A switch to either i.v. or oral antifungal monother-
apy should be considered in patients with stable
condition showing signs of clinical and/or radio-
logical improvement. 
Treatment recommendations (table 3 and figure 2)
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Setting First choice Alternatives Switch to oral medication
Primary (i.e upfront) Voriconazole (Vfend®) 6 mg/kg q12h i.v. Liposomal Amphotericin B (AmBisome®) Voriconazole (Vfend®) 400 mg/d
therapy of IA on day 1, then 4 mg/kg 2x/d i.v., Grade: AI 3–5 mg/kg/d i.v., Grade: BI Grade: AI
or Amphotericin B deoxycholate (Fungizone®)* or Itraconazole (Sporanox®) 400 mg/d, 
1 mg/kg/d i.v., Grade: CI Grade: BII
Refractory disease Caspofungin (Cancidas®) 70 mg i.v. (1st dose), Voriconazole (Vfend®) 400 mg/d, 
(ie salvage therapy) then 50 mg/d i.v., Grade: BII Grade: AI
or Voriconazole (Vfend®) if not used as or Itraconazole (Sporanox®) 400 mg/d, 
primary therapy, 6 mg/kg q12h i.v. on day 1, Grade: BII
then 4 mg/kg 2x/d i.v., Grade: BII
or Liposomal Amphotericin B (AmBisome®)
3–5 mg/kg/d i.v., Grade: BII
Combination therapy Caspofungin (Cancidas®) 70 mg i.v. (1st dose), Continue combination therapy 
(i.e critically ill patient) then 50 mg/d i.v. until patient is in stable condition,
plus Voriconazole (Vfend®)1 6 mg/kg q12h i.v. then switch to i.v. or oral monotherapy 
on day 1, then 4 mg/kg 2x/d i.v. (see above), Grade: CIII
or Liposomal Amphotericin B (AmBisome®) 
3–5 mg/kg/d i.v., Grade: CII
* See general comments in the footer of table 4
1 Voriconazole: can be used in combination even if it was failing as monotherapy
Duration of treatment for invasive aspergillosis: stop after resolution of all clinical + radiological symptoms/signs of infection. Grade: CIII
Table 3
Treatment recommendations for invasive aspergillosis.
Combination
therapy
(i.e critically ill
patient)
Voriconazole Caspofungin
plus Voriconazole
or liposomal
Amphotericin B
Caspofungin
or Voriconazole
or liposomal
Amphotericin B
Primary therapy
     (ie upfront)
Refractory disease
     (ie salvage)
Invasive Aspergillosis
Figure 2
Invasive 
Aspergillosis: 
Treatment Options.
For dosages and 
alternative drugs 
see table 3 and 4.
Rationale
Cancer patients at high risk of fungal infec-
tions are those with acute leukaemia or with allo-
genic hematopoietic stem cell transplantation
(HSCT) who have prolonged and profound neu-
tropenia or immunosuppression for graft-versus-
host disease. In contrast, patients with other
haematological malignancies (myeloma, lym-
phomas, chronic myelogenous or lymphocytic
leukaemia), solid tumours and recipients of an au-
tologous HSCT are at low risk of invasive mycoses
as neutropenia is typically of short duration and
immunosuppression is rather moderate. Adminis-
tration of empirical antifungal therapy has become
a standard of care in patients with neutropenia and
persistent fever despite treatment with broad-
spectrum antibiotics. The rationale for early ad-
ministration of antifungal agents in these patients
has been that clinically occult fungal infections
(primarily due to Candida or Aspergillus) are a fre-
quent autopsy finding in neutropenic patients and
that persistent fever is often the only early sign of
an invasive mycosis. 
Clinical trials
The concept of empirical antifungal therapy 
is supported by the results of two pioneer, albeit
not placebo-controlled, randomised studies con-
ducted in the 1980s, which showed that the empir-
ical use of amphotericin B in neutropenic patients
with prolonged fever of undetermined origin 
reduced the incidence of fungal infections and fun-
gal-related mortality [140, 141]. The benefit was
primarily observed in patients who were severely
neutropenic, who had not received antifungal pro-
phylaxis, or who had a clinically documented in-
fection [141]. Based on the results of these initial
studies, empirical administration of amphotericin
B deoxycholate became standard therapy in these
patients.
Empirical antifungal therapy in patients with neutropenia and persistent fever
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During the last two decades, more than 20 ran-
domised controlled clinical trials of empirical an-
tifungal therapy have been performed in patients
with neutropenia and persistent fever [8, 9, 46,
117, 140–158]. The vast majority of these studies
have compared the efficacy and safety of various
doses or formulations (ie conventional versus lipid
formulations) of amphotericin B with that of an
azole (ketoconazole or fluconazole) in an usually
limited number of patients and therefore lacked
power to detect small differences of efficacy or 
toxicity. We will therefore review the results of 
the most recent clinical trials that included a larger
patient population and that used a composite 
score of several clinical and laboratory criteria to
evaluate the response to therapy. In a non-infe-
riority (8 10%) study of 702 patients, liposomal
amphotericin B was shown to be as effective as 
amphotericin B deoxycholate (50% vs 49%), but
was associated with fewer breakthrough fungal
infections (3.2% vs 7.8%), less infusion-related
fever (17% vs 44%), chills and rigors (18% vs 54%)
and less nephrotoxicity (19% vs 34%) [8]. One
should note, however, that the daily dose of am-
photericin B deoxycholate (0.6 mg/kg/d) was mod-
erate and that there was no mentioning of fluid
loading to reduce amphotericin B deoxycholate
toxicity. 
Three clinical trials have compared the effi-
cacy and safety of an azole (fluconazole, itracona-
zole or voriconazole) to that of amphotericin B 
deoxycholate or liposomal amphotericin B. In a
study of 317 patients, favourable response rates oc-
curred in 68% of the patients treated with intra-
venous fluconazole and in 67% of the patients
treated with intravenous amphotericin B deoxy-
cholate [153]. Progressive or new fungal infections
occurred in a similar proportion of patients in the
two treatment groups (8% vs 6%, respectively),
but adverse events occurred more often in patients
treated with amphotericin B than in the flucona-
zole group (81% vs 13%, P = 0.001). Overall 
mortality and fungal infection-related mortality
were similar in both treatment groups. In a large,
open, non-inferiority (8 15%) study that included
384 patients, itraconazole was found to exhibit at
least equivalent efficacy in an intention-to-treat
analysis (47% vs 38%, difference: 9%, 95%CI:
–0.8 to 19.5%) and significantly fewer drug-
related adverse events, including nephrotoxicity
(5% vs 24%, P <0.001) than amphotericin B de-
oxycholate [155]. Interestingly, the response rate
to itraconazole was superior to that of ampho-
tericin B deoxycholate in patients who had previ-
ously received antifungal prophylaxis (48% vs
35%, difference: 13%, 95%CI: 1.6 to 24.8%).
Breakthrough fungal infections and mortality were
similar in both treatment groups. In the third
study, a non-inferiority (8 10%) multicentre trial
that included 837 patients, the overall success rates
were 26% for patients treated with voriconazole
and 31% for patients treated with liposomal am-
photericin B [156]. However, voriconazole did not
fulfill the statistical criteria for non-inferiority.
Voriconazole was superior to liposomal ampho-
tericin B for the prevention of breakthrough fun-
gal infections (1.9% vs 5.0%, P = 0.02), especially
in high-risk patients such as allogeneic transplants
and patients with relapsed leukaemia. Fewer cases
of infusion-related toxicity reactions (P <0.01) and
of nephrotoxicity (P <0.001), but more cases of
transient abnormal vision (P <0.001) and of hallu-
cinations (P <0.001) occurred in the voriconazole
group than in the liposomal amphotericin B group. 
Finally, the results of a recent large, double-
blind, multicentre study that included 1123 pa-
tients showed that caspofungin was as effective 
as (overall response rates: 33.9% vs 33.7%), and
better tolerated than lipososomal amphotericin B
[158]. Less infusion-related toxicity (35.1% vs
51.6%), nephrotoxicity (2.6% vs 11.5%), and pre-
mature discontinuation of study medication
(10.3% vs 14.5%) occurred in patients treated with
caspofungin than in those treated with liposomal
amphotericin B. In addition, caspofungin was 
superior to liposomal amphotericin B for the suc-
cessful outcome of baseline fungal infections
(51.9% vs 25.9%) and for survival rates 7 days after
therapy (92.6% vs 89.2%). 
Clinical trials of empirical antifungal therapy
for patients with neutropenia and persistent fever
performed during the last two decades have not re-
vealed a clear-cut superior antifungal agent in
terms of efficacy. A consistent finding of many
studies has been the increased risk of infusion-
related reactions and nephrotoxicity in patients
treated with amphotericin B deoxycholate and to
a lower extent with lipid formulations when com-
pared with azoles (fluconazole, itraconazole or
voriconazole) or echinocandins (caspofungin).
However, given that it is as active as and substan-
tially less expensive than most other antifungal
drugs on the market, amphotericin B deoxycholate
is recommended as first choice therapy for patients
with neutropenia and persistent fever. Close mon-
itoring of the appearance of adverse events in pa-
tients treated with amphotericin B deoxycholate is
mandatory. Should contra-indications be present
at baseline or develop during therapy (see footnote
table 4), liposomal amphotericin B, caspofungin,
itraconazole, or voriconazole are alternative treat-
ment options. However, azoles should not be used
for empirical antifungal therapy in patients receiv-
Treatment recommendations (table 4)
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ing fluconazole prophylaxis, as infections due to
azole-resistant non-albicans Candida species may
occur in this setting.
Treatment costs of the available treatment op-
tions differ substantially and are summarised in
table 5.
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Generic drug name Trade name Daily dosing and route Daily cost CHF
Amphotericin B deoxycholate Fungizone® 1 mg/kg i.v. 76
Liposomal Amphotericin B AmBisome® 3 mg/kg i.v. 1078
5 mg/kg i.v. 1796
Fluconazole Diflucan® 800 mg i.v. 185
400 mg i.v. 92
400 mg p.o. 41
Generic formulations 400 mg p.o. 25–33
Itraconazole Sporanox® 250 mg i.v. 243
400 mg/d p.o. (suspension) 25
400 mg/d p.o. (capsules) 19
Voriconazole Vfend® 6 mg/kg 2x i.v. 932
4 mg/kg 2x i.v. 699
400 mg/d p.o. 125
Caspofungin Cancidas® 70 mg i.v. 929
50 mg/d i.v. 731
Table 5
Daily hospital 
acquisition costs* 
of various antifungal
agents.
* Calculated for a 
patient with a body
weight of 70 kg 
(ex-factory prizes 
in Switzerland 
in 2005)
First choice Alternatives Switch to oral medication
Amphotericin B deoxycholate (Fungizone®)1 Liposomal Amphotericin B (AmBisome®) 3 mg/kg/d i.v., Itraconazole (Sporanox®)2 400 mg/d,
1 mg/kg/d i.v., Grade: AI Grade: AI or Caspofungin (Cancidas®)2 70 mg i.v. (1st dose), Grade: AI 
then 50 mg/d i.v. then 50 mg/d i.v., Grade: AI or Voriconazole (Vfend®)2 400 mg/d
or Voriconazole (Vfend®)2 6 mg/kg q12h i.v. on day 1, Grade: BII
then 4 mg/kg 2x/d i.v., Grade: BI
or Itraconazole (Sporanox®) 200 mg/d q12h i.v on day 1, 
then 200 mg/d i.v., Grade: BI
1 See general comments
2 Few clinical data available on the use of azoles and echinocandins in neutropenic patients with documented systemic candidiasis. Few clinical data available 
on the use of caspofungin in neutropenic patients with documented invasive aspergillosis. Azoles and echinocandins are not active against zygomycetes. 
Due to the increased risk of azole-resistant Candida infections, azoles should not be used in patients receiving fluconazole prophylaxis.
Duration of empirical antifungal treatment for persistent fever during neutropenia : until recovery from neutropenia + resolution of clinical/microbiological/
radiological symptoms/signs suggestive of invasive fungal infection. Grade: CIII 
GENERAL COMMENTS
Contraindications for the use of amphotericin B deoxycholate (Fungizone®):
– Serum creatinine >150 micromol/L, Grade: CIII
– History of toxicity which required discontinuation of therapy, Grade: CIII
– Concomitant medication with nephrotoxic drugs (eg aminoglycosides, cyclosporin), Grade: CIII
Toxicity criteria for discontinuation of therapy in patients receiving amphotericin B deoxycholate (Fungizone®): 
– Increase of serum creatinine: >2x baseline value (if normal at baseline), or >200 micromol/L (if baseline between upper normal limit and 150 micromol/L), 
Grade: CIII
– Debilitating infusion-related fever and chills persisting for >2 days despite infusion over 24 hours and symptomatic treatment including paracetamol 
+ opioid + anti-histaminic, Grade: CIII
Monitoring of voriconazole blood levels should be considered if underdosing is suspected or in presence of clinical symptoms/signs suggestive of 
drug-related toxicity. Grade: CIII
Monitoring of itraconazole blood levels routinely recommended. Grade: CIII
Table 4
Empirical antifungal therapy in patients with neutropenia and persistent fever.
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